Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun ...

Jaina Patel was in her early 30s when a bout of bronchitis led to her losing weight, her job, and eventually her sense of ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

根据VOYAGE研究的最新分析，度普利尤单抗作为一种针对2型炎症的单克隆抗体，能够有效减少哮喘加重事件并改善肺功能。研究表明，在基线时血液嗜酸性粒细胞计数在500至1500/μL之间的儿童中，接受度普利尤单抗治疗的患者，年度恶化率降低了67%。这一数据不仅让医学界为之振奋，也为家长们注入了信心。